# EU Medicines Panel Issues Positive Opinion on Revolution Medicines’ Rasonque

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/32781
Published: 2026-10-15T21:29:19.000Z
Updated: 2026-10-15T21:29:19.000Z
Section: Business

> The opinion covers second-line monotherapy for adults with metastatic pancreatic adenocarcinoma and was supported by Phase 3 study data.

On Oct. 15, the committee responsible for human medicines at the European Medicines Agency gave Revolution Medicines’ Rasonque (daraxonrasib) a positive opinion for adults with metastatic pancreatic adenocarcinoma.

The opinion covers the drug as a second-line monotherapy. It was supported by data from the Phase 3 RASolute study.